United Press International - Health Business - Bayer's Trasylol may cause kidney failure

United Press International - Health Business - Bayer's Trasylol may cause kidney failure: "WASHINGTON, Jan. 25 (UPI) -- A major independent study indicates Bayer's antifibrinolytic agent Trasylol doubles the risk of kidney failure and causes other serious adverse events, including stroke and heart attack.

The finding is likely to significantly impact sales of the drug, which were expected to be more than $600 million this year."

Bloomberg.com: Europe

Bloomberg.com: Europe: "Jan. 25 (Bloomberg) -- Bayer AG's Trasylol, used in more than 60 countries to control bleeding after surgery, doubles a patient's likelihood of developing kidney failure and increases the risk of heart attacks and strokes, researchers said."

Reuters Business Channel | Reuters.com

Reuters Business Channel | Reuters.com: "FRANKFURT, Jan 26 (Reuters) - Shares in German drugs and chemicals group Bayer (BAYG.DE: Quote, Profile, Research) fell more than 3 percent on Thursday after a study showed that its Trasylol drug doubled the risk of kidney failure.

Analysts said the result of the study, in the New England Journal of Medicine, increased the risk for investors from Bayer's pharmaceuticals business, which is recovering from a $1 billion recall of cholesterol drug Baycol over patient deaths."

Bayer blood clot drug Trasylol associated with increased health risks - study - Forbes.com

Bayer blood clot drug Trasylol associated with increased health risks - study - Forbes.com: "LEVERKUSEN, Germany (AFX) - Bayer AG's blood clot drug Trasylol (Aprotinin) has been associated with increased risk of kidney failure, of higher stroke risk and encephalopathy -- any degenerative disease of the brain -- in cardiac surgery, according to a study published in the New England Journal of Medicine. "

Bayer Slips On FDA Trasylol Warning | newratings.com

Bayer Slips On FDA Trasylol Warning | newratings.com: "Bayer (BAY.ETR) -1.4% at EUR33.39, hemorrhaging slightly on back of FDA's warning on its Trasylol blood drug, say traders. Within a few minutes, around 700,000 shares were traded, says one. 'But that's an old story,' another trader says pointing to a previous study of the drug from January. (MOD/HAD)"

Vioxx expected to drag on Merck 2005 and play key role in 2006 performance

Vioxx expected to drag on Merck 2005 and play key role in 2006 performance: "Vioxx is expected to drag down Merck & Co.'s 2005 earnings when they are reported Tuesday. But what's really frustrating analysts is their inability to assess the drug's potential liability and the toll that litigation preparations are taking on the company." [Canoe Money]

Zyprexa hurt Lilly revenue growth in '05

Zyprexa hurt Lilly revenue growth in '05 | IndyStar.com: "Struggling to replace eroding sales from its No. 1 drug Zyprexa, Eli Lilly and Co. managed to post revenue growth of just 6 percent last year, its smallest increase since 2002." [IndyStar.com]